公开(公告)号：US20180221336A1

公开(公告)日：2018-08-09

申请号：US15866293

申请日：2018-01-09

Applicant: SteadyMed, Ltd.

Inventor： Peter Noymer ,  Michael Laird Hurrey

IPC: A61K31/407 ,  A61P29/00 ,  A61M5/142

CPC classification number: A61K31/407 ,  A61K9/0019 ,  A61K9/08 ,  A61M5/14248 ,  A61M2005/14208 ,  A61P29/00

Abstract: The invention provides a unit dosage form of Ketorolac providing for a reduced dosage than typically provided to a subject in need of same, wherein said dosage form of Ketorolac is in a sterile fluid composition formulated for continuous subcutaneous delivery via body-worn infusion pump assembly, and wherein said Ketorolac is present at a concentration of between 40 mg/mL and 240 mg/mL formulated for single use delivery in a volume not to exceed 1-10 mL. Methods of use of same, body-worn infusion pump assemblies containing same and containers containing same for incorporation within a body-worn infusion pump assembly for a dose-sparing formulation comprising Ketorolac are also provided.

公开(公告)号：US20200054754A1

公开(公告)日：2020-02-20

申请号：US16609544

申请日：2018-05-10

Applicant: SteadyMed Ltd.

Inventor： Michael Laird Hurrey ,  Drazen Ostovic ,  Peter Noymer

IPC: A61K47/12 ,  A61K47/02 ,  A61P23/02 ,  A61K31/445

Abstract: This invention describes compositions comprising at least 75 mg/mL of solubilized otherwise poorly soluble drug in an aqueous environment, wherein the composition further comprises a combination of 3 or more acids. Methods of providing analgesia, anti-pyretic effects or reducing pain in a subject presenting with a pain condition, and methods of reducing administration site irritation, inflammation or a combination thereof in a subject presenting with a pain condition, comprising the steps of administering such compositions and infusion pumps containing such compositions are also described.

公开(公告)号：US20180193460A1

公开(公告)日：2018-07-12

申请号：US15866345

申请日：2018-01-09

Applicant: SteadyMed, Ltd.

Inventor： Michael Laird Hurrey ,  Peter Noymer

IPC: A61K47/18 ,  A61K31/407 ,  A61K9/00 ,  A61M5/142

CPC classification number: A61K47/183 ,  A61K9/0019 ,  A61K31/407 ,  A61K47/12 ,  A61M5/14248 ,  A61P29/00

Abstract: Embodiments provide a more efficacious and/or more comfortable, consistent and reliable Ketorolac treatment for patients in need of same, which in some aspects yields a formulation that is much more stable over time. In some aspects, there is provided a Ketorolac-containing formulation adapted to contain specific stabilizers in an ethanol free setting and/or sodium chloride free setting, which provides for enhanced formulation stability. In some aspects, such formulation is characterized by enhanced stability even when the formulation is stored at room temperature, or in some embodiments, when the formulation is stored at higher temperatures, such as, for example, that experienced in the United States in various states, in various seasons outdoors, etc. In some aspects, such enhanced stability is in addition to other advantages as described herein, for example, for example, in terms of a dose sparing effect, and others, as described herein.